Neuroone Medical Technologies (NMTC) Liabilities and Shareholders Equity (2010 - 2026)

Neuroone Medical Technologies (NMTC) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $7.6 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 69.83% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.8 million (up 77.79% YoY) and the FY2025 annual result came in at $10.8 million, up 100.85% from the prior year.
• Liabilities and Shareholders Equity fell to $7.6 million in Q1 2026, from $8.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $14.1 million in Q1 2022 to a low of $4.5 million in Q1 2025.
• A 5-year average of $8.2 million and a median of $7.6 million in 2026 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity tumbled 50.24% — and 2025, when it soared 120.24%.
• Tracing NMTC's Liabilities and Shareholders Equity over 5 years: stood at $9.7 million in 2022, then tumbled by 39.73% to $5.8 million in 2023, then rose by 11.54% to $6.5 million in 2024, then surged by 32.08% to $8.6 million in 2025, then fell by 11.76% to $7.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $7.6 million (Q1 2026), $8.6 million (Q4 2025), and $10.8 million (Q3 2025), per Business Quant data.